DBT-12733

DBT-12733 is an investigational **small-molecule cannabinoid receptor modulator** being developed by Diverse Biotech for **glioblastoma**. It has been described as part of a novel class of anticancer agents derived from improved cannabinoid chemistry, with molecules designed to combine cannabinoid-like properties with chemotherapy-like tumor-killing activity. Publicly available preclinical information indicates that DBT-12733 has shown cytotoxic activity against glioblastoma cells, including activity in the temozolomide-resistant T98G cell line, and the program received **FDA Orphan Drug Designation** for glioblastoma on May 4, 2020. The exact receptor subtype selectivity, binding mode, formulation, route, and full clinical pharmacology have not been clearly disclosed in the provided materials.